Chugai Pharmaceutical Co Ltd (4519.T)
4519.T on Tokyo Stock Exchange
5,880JPY
9:00pm EDT
5,880JPY
9:00pm EDT
Change (% chg)
¥200 (+3.52%)
¥200 (+3.52%)
Prev Close
¥5,680
¥5,680
Open
¥5,740
¥5,740
Day's High
¥5,880
¥5,880
Day's Low
¥5,730
¥5,730
Volume
251,200
251,200
Avg. Vol
869,183
869,183
52-wk High
¥6,080
¥6,080
52-wk Low
¥3,925
¥3,925
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- ownership
- filings
- deals
- private equity
- third-party document and information retrieval
- estimates
- fundamentals
- economics
- events
- news
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
Name | Age | Since | Current Position |
---|---|---|---|
Osamu Nagayama |
70 | 2018 | Chairman of the Board, Representative Director |
Tatsuro Kosaka |
65 | 2018 | President, Chief Executive Officer, Representative Director |
Motoo Ueno |
60 | 2012 | Vice Chairman of the Board, Representative Director |
Toshiaki Itagaki |
2017 | Chief Financial Officer, Senior Executive Officer, Director of Finance & Accounting, Senior Manager of IT, Senior Manager of Finance | |
Junichi Ebihara |
2017 | Senior Executive Officer, Director of Legal Affairs |
- BRIEF-Chugai Pharmaceutical To Invest 25 Bln Yen Into A Singapore Research Center By 2021-Nikkei
- BRIEF-Chiome Bioscience says termination of joint research contract
- BRIEF-Chugai Pharmaceutical says change of chief executive officer
- BRIEF-R&I affirms Chugai Pharmaceutical's rating at "AA-" and says stable outlook -R&I
- Roche's Chugai transfers rights of 13 Long-Term Listed Products to Taiyo